254.46
5.53 (2.22%)
| Previous Close | 248.93 |
| Volume | 1,210,726 |
| Price / Earnings (Forward) | 16.11 |
| Price / Sales | 3.59 |
| Price / Book | 1.94 |
| 52 Weeks Range |
| Profit Margin | 15.07% |
| Operating Margin (TTM) | 28.05% |
| Diluted EPS (TTM) | 10.12 |
| Quarterly Revenue Growth (YOY) | 6.10% |
| Quarterly Earnings Growth (YOY) | -38.90% |
| Total Debt/Equity (MRQ) | 39.00% |
| Current Ratio (MRQ) | 1.44 |
| Operating Cash Flow (TTM) | 2.58 B |
| Levered Free Cash Flow (TTM) | 3.43 B |
| Return on Assets (TTM) | 5.43% |
| Return on Equity (TTM) | 9.19% |
AIStockmoo Score
| Value 30% | 1.7 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 1.7 |
| Timing 30% | 3.0 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | 1.5 |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | 0.0 |
| Insider Activity info | 0.0 |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Environment | ×1.00 |
| Macro Environment info | -1.3 |
| Sector vs Market (6M) | +10.3% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -5.0 |
| Final Score | 1.77 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Biogen Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BIIB | - | - | - | 1.94 |
| GRFS | - | 1.07% | - | 0.900 |
| SNY | - | 5.01% | - | 1.40 |
| GILD | - | 1.93% | - | 16.00 |
| AMGN | - | 2.14% | - | 17.60 |
| MIRA | - | - | - | 3.34 |
Select this tab to load the latest available analysis.
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 92.79% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |